Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGB-290 · 2 trials · 2 indications
ORR is defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), assessed by IRC per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
The primary endpoint of the study was a composite response rate that included ORR, a ≥50% decrease in serum prostate-specific antigen (PSA), and/or a decrease in circulating tumor cells.
The primary endpoint of the study was a composite response rate that included ORR, a ≥50% decrease in serum prostate-specific antigen (PSA), and/or a decrease in circulating tumor cells.
Primary PK parameter is area under the plasma concentration time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUClast).
Primary PK parameter is area under plasma concentration time curve (AUC).
Primary PK parameter is maximum observed plasma concentration (Cmax).
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Triple-negative breast cancer (TNBC) | EXPERIMENTAL | Locally advanced or metastatic TNBC |
| Cohort 2: HR(+)/HER2(-) breast cancer | EXPERIMENTAL | Locally advanced or metastatic Hormone receptor-positive(HR+) human epidermal growth factor receptor2 Negative(HER2-) breast cancer |
| ovarian cancer, fallopian cancer, or primary peritoneal cancer | EXPERIMENTAL | 60mg BID oral. |
| Breast Cancer | EXPERIMENTAL | 60mg BID Ora |
| Prostate Cancer | EXPERIMENTAL | 60mg BID Oral |
| Small Cell Lung Cancer | EXPERIMENTAL | 60mg BID Oral |
| Gastric Cancer | EXPERIMENTAL | 60mg BID Oral |
| Name | Type | Description |
|---|---|---|
| BGB-290 | DRUG | Administered orally |
Inclusion Criteria: 1. Confirmed deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation 2. Locally advanced or metastatic breast cancer despite standard therapy and the following: 1. Histologically or cytologically confirmed HER2(-) breast cancer (TNBC or estrogen receptor-positi...
BGB-290 is an investigational small molecule being studied in oncology. It has been evaluated in a Phase 1 trial for participants with advanced solid tumors who failed previous lines of treatment, and in a Phase 2 trial for metastatic HER2-negative breast cancer patients with BRCA mutations in China.
BGB-290 is being developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company is conducting clinical trials for this investigational oncology drug.
BGB-290 has completed a Phase 1 trial (NCT02361723) for advanced solid tumors and a Phase 2 trial (NCT03575065) for HER2-negative breast cancer. It is an investigational drug still in clinical development and is not FDA approved.
BGB-290 has been studied in two completed trials: NCT02361723, a Phase 1a/1b trial for advanced solid tumors in Australia with 101 participants, and NCT03575065, a Phase 2 trial for metastatic HER2-negative breast cancer with BRCA mutations in China with 88 participants.
BGB-290 is the code name for the drug also known as pamiparib. It is a small molecule being developed by BeOne Medicines Ltd. for oncology indications, including advanced solid tumors and HER2-negative breast cancer.